CA2608515A1 - Production of multivalent virus like particles - Google Patents

Production of multivalent virus like particles Download PDF

Info

Publication number
CA2608515A1
CA2608515A1 CA002608515A CA2608515A CA2608515A1 CA 2608515 A1 CA2608515 A1 CA 2608515A1 CA 002608515 A CA002608515 A CA 002608515A CA 2608515 A CA2608515 A CA 2608515A CA 2608515 A1 CA2608515 A1 CA 2608515A1
Authority
CA
Canada
Prior art keywords
virus
peptide
capsid fusion
fusion peptide
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002608515A
Other languages
English (en)
French (fr)
Inventor
Lada Rasochova
Philip Phuoc Dao
Jamie P. Phelps
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfenex Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2608515A1 publication Critical patent/CA2608515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002608515A 2005-06-01 2006-06-01 Production of multivalent virus like particles Abandoned CA2608515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68654105P 2005-06-01 2005-06-01
US60/686,541 2005-06-01
PCT/US2006/021262 WO2007053188A2 (en) 2005-06-01 2006-06-01 Production of multivalent virus like particles

Publications (1)

Publication Number Publication Date
CA2608515A1 true CA2608515A1 (en) 2007-05-10

Family

ID=38006346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002608515A Abandoned CA2608515A1 (en) 2005-06-01 2006-06-01 Production of multivalent virus like particles

Country Status (9)

Country Link
US (1) US20070041999A1 (cg-RX-API-DMAC7.html)
EP (1) EP1885394A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009501001A (cg-RX-API-DMAC7.html)
KR (1) KR20080018176A (cg-RX-API-DMAC7.html)
CN (1) CN101287489A (cg-RX-API-DMAC7.html)
AU (1) AU2006309286A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0611336A2 (cg-RX-API-DMAC7.html)
CA (1) CA2608515A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007053188A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021391A1 (en) * 2006-07-14 2010-01-28 Montana State University Novel nanoparticles for biofilm targeting
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
WO2009033004A1 (en) * 2007-09-07 2009-03-12 Montana State University Protein cages and their uses
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
PL3597757T3 (pl) * 2012-05-11 2021-05-31 Medicago Inc. Wytwarzanie cząstek podobnych do rotawirusów w roślinach
US10086062B2 (en) 2012-07-05 2018-10-02 Ohio State Innovation Foundation Infectious pancreatic necrosis virus (IPNV) vaccine compositions
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
EP3089755A1 (en) * 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
CN105018463A (zh) * 2015-06-05 2015-11-04 北京百迈客生物科技有限公司 一种用于次生代谢物含量高的植物组织的dna提取方法
KR101830792B1 (ko) * 2016-01-27 2018-02-21 건국대학교 산학협력단 항균 펩타이드를 포함하는 불용성 융합단백질 및 이를 이용한 항균 펩타이드의 제조 방법
CN108558990A (zh) * 2018-01-05 2018-09-21 山东省科学院生态研究所 肿瘤靶向肽f3修饰的豇豆褪绿斑驳病毒样颗粒的构建、表达及其应用
US20230038487A1 (en) * 2019-11-25 2023-02-09 The Regents Of The University Of California Modified viral therapeutics and uses thereof
US20250108108A1 (en) * 2020-04-14 2025-04-03 The Regents Of The University Of California Hybrid flu-coronavirus vaccine
CN117098553A (zh) 2020-11-11 2023-11-21 加州理工学院 多价载体和相关疫苗组合物
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
AU742409B2 (en) * 1997-09-05 2002-01-03 Medimmune, Llc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
KR100312456B1 (ko) * 1999-03-13 2001-11-03 윤덕용 슈도모나스 플루오레슨스 유래의 외래단백질 분비촉진유전자
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US7135282B1 (en) * 1999-10-14 2006-11-14 The Dow Chemical Company Viral particles with exogenous internal epitopes
GB9924352D0 (en) * 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2003068804A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
WO2003087129A2 (en) * 2002-04-08 2003-10-23 Siga Technologies, Inc. Immunogenic peptides, and method of identifying same
JP2006507800A (ja) * 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
MXPA05000287A (es) * 2002-07-05 2005-09-08 Leclerc Denis Particula viral adyuvante.
WO2005005614A2 (en) 2003-07-03 2005-01-20 Pecos Labs, Inc. Combined b-cell and t-cell epitopes on vlp for improved vaccines
AU2004255470B2 (en) * 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
CA2547511A1 (en) * 2003-12-01 2005-07-28 Dow Global Technolgies Inc. Recombinant icosahedral virus like particle production in pseudomonads

Also Published As

Publication number Publication date
WO2007053188A3 (en) 2007-12-06
BRPI0611336A2 (pt) 2010-08-31
EP1885394A2 (en) 2008-02-13
EP1885394A4 (en) 2009-10-21
KR20080018176A (ko) 2008-02-27
JP2009501001A (ja) 2009-01-15
WO2007053188A2 (en) 2007-05-10
US20070041999A1 (en) 2007-02-22
CN101287489A (zh) 2008-10-15
AU2006309286A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US20070041999A1 (en) Production of multivalent virus like particles
Peacey et al. Versatile RHDV virus‐like particles: Incorporation of antigens by genetic modification and chemical conjugation
US7666624B2 (en) Modified plant viruses and methods of use thereof
AU2004313458B2 (en) Recombinant icosahedral virus like particle production in pseudomonads
US20130236491A1 (en) Spherical nano and microparticles derived from plant viruses for the display of foreign proteins or epitopes
CN104271594B (zh) 用于初免‑加强疫苗的水疱性口炎病毒
JP2009502789A (ja) 組み換えインフルエンザワクチン
US20070128213A1 (en) Novel plant virus particles and methods of inactivation thereof
CA2557668A1 (en) High efficiency peptide production in plant cells
US20090093019A1 (en) Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
CN110893234A (zh) 一种犬瘟热、犬细小病毒病、狂犬病三联亚单位疫苗
JP2023519837A (ja) コロナウイルスを処置するためのワクチン組成物
Walker et al. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins
US20070207167A1 (en) Immunologically enhanced recombinant vaccines
Manuel-Cabrera et al. Immune response to a potyvirus with exposed amino groups available for chemical conjugation
CZ20021303A3 (cs) Virové částice s exogenními epitopy uvnitř částice
CN107624117A (zh) 基于乙型肝炎核心抗原的疫苗
WO2025260018A1 (en) Particle delivery for self-amplifying vaccines
JP2012139193A (ja) 融合タンパク質
TW202311281A (zh) 一種自組裝蛋白質奈米粒子及其應用
Green The development and use of antigen-antibody-LTB (Ag-MAb-LTB) complexes as immunogens
LV15007B (lv) Kartupeļu vīrusam PVM līdzīgo daļiņu iegūšana

Legal Events

Date Code Title Description
FZDE Discontinued